At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TERN Terns Pharmaceuticals, Inc.
Pre-Mkt 03-20 08:44:12 EDT
49.06
+1.28
+2.68%
盘前49.99
+0.93+1.90%
08:40 EDT
High49.53Low46.75Vol3.62M
Open47.26D1 Closing47.78Amplitude5.82%
Mkt Cap5.35BTradable Cap3.94BTotal Shares109.00M
T/O176.29MT/O Rate4.50%Tradable Shares80.32M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

U.S. Earnings Preview: After Market Close March 18
Dow Jones  ·  03-19 03:31
U.S. Earnings Preview: After Market Close March 18
Terns Pharmaceuticals CEO Amy L. Burroughs disposes of USD 681,073 in common shares
Reuters  ·  03-18 06:11
Terns Pharmaceuticals CEO Amy L. Burroughs disposes of USD 681,073 in common shares
Unusually active option classes on open March 13th
TIPRANKS  ·  03-13
Unusually active option classes on open March 13th
Terns Pharmaceuticals publishes corporate presentation on TERN-701 oral allosteric BCR-ABL inhibitor for CML with 75% MMR at 24 weeks
Reuters  ·  03-10
Terns Pharmaceuticals publishes corporate presentation on TERN-701 oral allosteric BCR-ABL inhibitor for CML with 75% MMR at 24 weeks
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
GlobeNewswire  ·  02-26
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Reaffirming Buy on Terns Pharmaceuticals: Strong Early TERN-701 Data Drive Upgraded Long-Term Revenue Outlook and Upside Potential
TIPRANKS  ·  02-19
Reaffirming Buy on Terns Pharmaceuticals: Strong Early TERN-701 Data Drive Upgraded Long-Term Revenue Outlook and Upside Potential
Terns Pharmaceuticals CEO Amy L. Burroughs Disposes of Common Shares
Reuters  ·  02-19
Terns Pharmaceuticals CEO Amy L. Burroughs Disposes of Common Shares
Leerink Partners Initiates Coverage on Terns Pharmaceuticals With Outperform Rating, $58 Price Target
MT Newswires Live  ·  02-09
Leerink Partners Initiates Coverage on Terns Pharmaceuticals With Outperform Rating, $58 Price Target
Terns Pharmaceuticals initiated with an Outperform at Leerink
TIPRANKS  ·  02-09
Terns Pharmaceuticals initiated with an Outperform at Leerink
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Terns Pharmaceuticals (TERN)
TIPRANKS  ·  02-05
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Terns Pharmaceuticals (TERN)
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update
Simply Wall St.  ·  02-04
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update
BRIEF-Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule
Reuters  ·  02-03
BRIEF-Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule
What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders
Simply Wall St.  ·  02-02
What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders
Mizuho Securities Sticks to Their Buy Rating for Terns Pharmaceuticals (TERN)
TIPRANKS  ·  01-23
Mizuho Securities Sticks to Their Buy Rating for Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals Expands Global Rights to TERN-701
TIPRANKS  ·  01-23
Terns Pharmaceuticals Expands Global Rights to TERN-701
Terns Pharmaceuticals Inc - Amends License Agreement With Hansoh Healthtech - SEC Filing
THOMSON REUTERS  ·  01-23
Terns Pharmaceuticals Inc - Amends License Agreement With Hansoh Healthtech - SEC Filing
Terns Pharmaceuticals: Obligated to Pay Hansoh One-Time Upfront License Fee $1.0 Mln & Tiered Royalties 0.75% to 1.25% on Annual Net Sales
THOMSON REUTERS  ·  01-23
Terns Pharmaceuticals: Obligated to Pay Hansoh One-Time Upfront License Fee $1.0 Mln & Tiered Royalties 0.75% to 1.25% on Annual Net Sales
Assessing Terns Pharmaceuticals (TERN) Valuation After New TERN-701 Data And Capital Raise
Simply Wall St.  ·  01-18
Assessing Terns Pharmaceuticals (TERN) Valuation After New TERN-701 Data And Capital Raise
How Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data
Simply Wall St.  ·  01-16
How Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data
De-Risked CML Lead Asset, Robust Trial Strategy, and $1B Cash Runway Underscore Buy Rating on Terns Pharmaceuticals
TIPRANKS  ·  01-13
De-Risked CML Lead Asset, Robust Trial Strategy, and $1B Cash Runway Underscore Buy Rating on Terns Pharmaceuticals

Introduction

Company Name.
Terns Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Issue price:
--